Trigemino-autonome Kopfschmerzen in der Praxis

ZUSAMMENFASSUNG

Die Gruppe der trigemino-autonome Kopfschmerzen (TAK) beschreibt verschiedene primäre Kopfschmerzsyndrome, die durch ihr streng einseitiges Auftreten, die hohe Intensität der Schmerzattacken sowie den namensgebenden autonomen Begleitsymptomen wie Ptosis, Lakrimation und/oder Rhinorrhoe gekennzeichnet sind. Die Internationale Kopfschmerzklassifikation ICHD-3 unterteilt sie in den Clusterkopfschmerz, die paroxysmale Hemikranie, die Short-lasting unilateral neuralgiform headache attacks sowie in die Hemicrania continua. Allen TAK ist gemein, dass sie mit hohem individuellen Leidensdruck der Patienten einhergehen, jedoch potenziell behandelbar sind; in einigen Fällen sogar exzellent und hochspezifisch, weshalb Neurologen diese Syndrome kennen sollten.

ABSTRACT

The trigeminal autonomic cephalalgias (TAC) are a group of primary headaches characterized by their strictly unilateral occurrence, the high intensity of pain attacks, as well as eponymous autonomic symptoms, such as ptosis, lacrimation, and/or rhinorrhea. The international headache classification (ICHD-3) subdivides this group into cluster headache (CH), paroxysmal hemicrania (PH), short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA), and hemicrania continua (HC). All TAC have in common that they pose a high disease burden on patients, but are potentially treatable, in some instances highly specific, which is why neurologist ought to know these syndromes.

Schlüsselwörter

Clusterkopfschmerz - paroxysmale Hemicranie - Hemicrania continua - SUNC

Key words

Cluster headache - paroxysmal hemicrania - hemicrania continua - SUNCT

Publication History

Article published online:
09 March 2021

• Literatur

• 1 Goadsby PJ, Cittadini E, Cohen AS. Trigeminal Autonomic Cephalalgias: Paroxysmal Hemicrania, SUNCT/SUNA, and Hemicrania Continua. Semin Neurol 2010; 30: 186-191
• 2 Classification Committee of the IHS. The International Classification of Headache Disorders, 3rd edition, ICHD-3. Cephalalgia 2018; 38: 1-211
• 3 Russell MB. Epidemiology and genetics of cluster headache. The Lancet Neurology 2004; 3: 279-283
• 4 Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. The Lancet Neurology 2018; 17: 75-83
• 5 Manzoni GC. Gender ratio of cluster headache over the years: a possible role of changes in lifestyle. Cephalalgia 1998; 18: 138-142
• 6 Manzoni GC. Cluster headache and lifestyle: remarks on a population of 374 male patients. Cephalalgia 1999; 19: 88-94
• 7 Ferrari A, Zappaterra M, Righi F. et al Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey. J Headache Pain 2013; 14: 48
• 8 Ziegeler C, May A. Pathophysiologie der Migräne. Nervenheilkunde 2019; 38: 722-727
• 9 Edvinsson L, Haanes KA, Warfvinge K. et al CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nature Reviews Neurology 2018; 14: 338
• 10 Snoer A, Vollesen ALH, Beske RP. et al Calcitonin gene-related peptide and disease activity in cluster headache. Cephalalgia 2019; 39: 575-584
• 11 May A, Bahra A, Büchel C. et al Hypothalamic activation in cluster headache attacks. The Lancet 1998; 352: 275-278
• 12 Schulte LH, Haji AA, May A. Phase dependent hypothalamic activation following trigeminal input in cluster headache. The Journal of Headache and Pain 2020; 21: 30
• 13 May A, Evers S, Brössner G. et al Leitlinie zur Diagnostik, Therapie und Prophylaxe von Cluster-Kopfschmerz, anderen trigeminoautonomen Kopfschmerzen, schlafgebundenem Kopfschmerz und idiopathisch stechenden Kopfschmerzen: Überarbeitete Therapieempfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft in Zusammenarbeit mit der DGN, ÖKSG, SKG. Nervenheilkunde 2016; 35: 137-151
• 14 Goadsby PJ, Dodick DW, Leone M. et al Trial of Galcanezumab in Prevention of Episodic Cluster Headache. New England Journal of Medicine 2019; 381: 132-141
• 15 Goadsby PJ, Sahai-Srivastava S, Kezirian EJ. et al Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. Lancet Neurol 2019; 18: 1081-1090
• 16 Anonymous. Emgality. European Medicines Agency 2018. Im Internet https://www.ema.europa.eu/en/medicines/human/EPAR/emgality
• 17 Silvestro M, Tessitore A, Clemente FS dI. et al Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series. Headache: The Journal of Head and Face Pain 2020; 60: 1187-1195
• 18 Ansarinia M, Rezai A, Tepper SJ. et al Electrical Stimulation of Sphenopalatine Ganglion for Acute Treatment of Cluster Headaches. Headache: The Journal of Head and Face Pain 2010; 50: 1164-1174
• 19 Schoenen J, Jensen RH, Lantéri-Minet M. et al Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia 2013; 33: 816-830
• 20 Goadsby PJ, de Coo IF, Silver N. et al Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia 2018; 38: 959-969
• 21 Ziegeler C, May A. Facial paroxysmal hemicrania associated with the menstrual cycle. Cephalalgia Reports 2019; 2: 2515816319857070
• 22 Prakash S, Patell R. Paroxysmal Hemicrania: An Update. Current Pain and Headache Reports. 2014: 18 Im Internet http://link.springer.com/10.1007/s11916-014-0407-6
• 23 Ziegeler C, May A. Facial presentations of migraine, TACs, and other paroxysmal facial pain syndromes. Neurology 2019; 93: e1138
• 24 Sjaastad O, Saunte C, Salvesen R. et al Shortlasting, Unilateral Neuralgiform Headache Attacks with Conjunctival Injection, Tearing, Sweating, and Rhinorrhea: Cephalalgia. 2016 Im Internet https://journals.sagepub.com/doi/10.1046/j.1468-2982.1989.0902147.x?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
• 25 May A. About the understanding of classifications using SUNCT and SUNA as an example. Neurology 2019; 93: 523-525
• 26 Lambru G, Rantell K, Levy A. et al A prospective comparative study and analysis of predictors of SUNA and SUNCT. Neurology 2019: 10 DOI: 1212/WNL.0000000000008134
• 27 Antonaci F, Fredriksen T, Pareja JA. et al Shortlasting, Unilateral, Neuralgiform, Headache Attacks with Conjunctival Injection, Tearing, Sweating and Rhinorrhea: The Term and New View Points. Frontiers in Neurology 2018: 9
• 28 Favoni V, Grimaldi D, Pierangeli G. et al SUNCT/SUNA and neurovascular compression: New cases and critical literature review: Cephalalgia. 2013 Im Internet https://journals.sagepub.com/doi/10.1177/0333102413494273?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
• 29 Peres MFP, Silberstein SD, Nahmias S. et al Hemicrania continua is not that rare. Neurology 2001; 57: 948-951
• 30 May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology 2016; 12: 455-464